Merck's latest earnings call revealed a mix of growth and pain points for the pharmaceutical giant.

Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...

Investors have taken to punishing pharma companies that appear unable to gauge demand for their top products. Consider Pfizer. The company’s inability to accurately project demand for its Covid-19 ...

Merck plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on ...

Merck's full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

Along with other products, Merck is banking on the drug’s blockbuster potential to help offset Keytruda’s expected loss of exclusivity toward the end of the decade.

The drug remains a major earner for Merck, with sales still running in ... It set a target of launching a new product every 18 months. pharmaphorum sits down for a quick chat with the Grove.AI ...

Morgan Stanley analyst Terence Flynn has maintained their neutral stance on MRK stock, giving a Hold rating yesterday.Invest with Confidence: ...

Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...

Merck boasts more than six blockbuster drugs in its portfolio ... on the drug and should look for ways to diversify its product lineup.

Merck blamed the lower than expected forecast on the decision to pause shipments of its Gardasil vaccine to China until at least mid-year. Gardasil is given to patients to prevent human papillomavirus ...

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...